# Alzheimer's Disease Research Center

> **NIH NIH P30** · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2020 · $3,318,934

## Abstract

Since its inception in 1990, the Alzheimer's Disease Research Center (ADRC) at New York University Langone
Health has facilitated pioneering research to define transitions from normal aging to the subjective cognitive
decline (SCD), mild cognitive impairment (MCI), and early dementia stages of AD; as well as AD biomarker
development. Here we propose to continue this long-standing successful research direction with a focus on
understanding disease heterogeneity and delineating biomarkers and their role in these transitions, with
the long-term goal of helping to develop novel interventions that will delay or prevent cognitive decline.
The NYU ADRC has built an infrastructure that supports innovative research on AD and related dementias
(ADRD) to help achieve the NAPA goal of a cure by 2025. This will be facilitated by our nine highly successful
and interactive Cores (Admin; Clinical; Data Management & Statistical [DMS]; Neuropathology; Outreach,
Education & Engagement [ORE]; Neuroimaging; Biomarker; Psychosocial; and Research Education Component
[REC]). Together, our highly integrated cores will achieve the following aims: Aim 1. Enhance the performance
of innovative research in ADRC by maintaining nine cores that focus on delineating biomarkers of the transitions
from normal aging to SCD, MCI, and early dementia, and determining their roles to help develop novel
interventions that delay or prevent these transitions. We will also facilitate training in this area. Aim 2. Contribute
to the national network of ADRCs by providing clinical data, autopsy diagnoses, neuroimaging and biosamples
to NACC and NCRAD, as well as to other research community collaborative efforts in ADRD. Aim 3. Recruit and
retain a diverse subject population from clinical and community settings, via the ORE and Psychosocial Cores,
with concomitant engagement of the local scientific and lay community in ADRD with seminars, poster sessions
and the developmental projects via the Admin, ORE, and REC Cores. Aim 4. Foster the development of novel
avenues of investigation with methodological developments by the cores (via innovative cognitive assessments,
neuroimaging techniques, biomarkers and proteomic approaches), and encourage, recruit, and select
developmental projects. Aim 5. Accelerate translational research across the ADRD spectrum by using
biomarkers to better define the underlying disease heterogeneity and foster the development of novel therapeutic
interventions that consider this heterogeneity. Aim 6. Facilitate the education and training of a diverse ADRD
workforce. Our Center will enhance the scientific community's understanding of ADRD and expand the next
generation of diverse ADRD scientists, via combined efforts of the Admin, ORE, and REC Cores. In summary,
the NYU ADRD has facilitated pioneering research that defined the stage transitions from normal aging to
dementia, and contributed to AD biomarker development from its inception. In the next five years of funding, t...

## Key facts

- **NIH application ID:** 9921985
- **Project number:** 1P30AG066512-01
- **Recipient organization:** NEW YORK UNIVERSITY SCHOOL OF MEDICINE
- **Principal Investigator:** THOMAS M WISNIEWSKI
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $3,318,934
- **Award type:** 1
- **Project period:** 2020-05-01 → 2025-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9921985

## Citation

> US National Institutes of Health, RePORTER application 9921985, Alzheimer's Disease Research Center (1P30AG066512-01). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9921985. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*